TuHURA Biosciences Files 8-K
Ticker: HURA · Form: 8-K · Filed: Nov 25, 2024 · CIK: 1498382
Sentiment: neutral
Topics: disclosure, financials
TL;DR
TuHURA Biosciences filed an 8-K on 11/25/24. Check it for Reg FD and financials.
AI Summary
TuHURA Biosciences, Inc. filed an 8-K on November 25, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Kintara Therapeutics, Inc., is incorporated in Nevada and headquartered in Tampa, Florida.
Why It Matters
This filing provides important updates and disclosures for investors regarding TuHURA Biosciences, Inc., including financial information and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically contains standard disclosures and financial information without immediate significant operational changes.
Key Numbers
- 001-37823 — SEC File Number (Identifies the company's filing history with the SEC.)
- 99-0360497 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- TuHURA Biosciences, Inc. (company) — Registrant
- Kintara Therapeutics, Inc. (company) — Former company name
- November 25, 2024 (date) — Date of report
- Nevada (jurisdiction) — State of incorporation
- Tampa, Florida (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose is to report a Regulation FD Disclosure and to file Financial Statements and Exhibits, as indicated in the filing details.
When was this 8-K filed?
This 8-K was filed on November 25, 2024.
What was TuHURA Biosciences, Inc. formerly known as?
TuHURA Biosciences, Inc. was formerly known as Kintara Therapeutics, Inc.
In which state is TuHURA Biosciences, Inc. incorporated?
TuHURA Biosciences, Inc. is incorporated in Nevada.
What is the principal executive office address for TuHURA Biosciences, Inc.?
The principal executive office is located at 10500 University Dr., Suite 110, Tampa, Florida 33612.
Filing Stats: 1,713 words · 7 min read · ~6 pages · Grade level 14.8 · Accepted 2024-11-25 08:55:23
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HURA The Nasdaq
Filing Documents
- hura-20241125.htm (8-K) — 64KB
- hura-ex99_1.htm (EX-99.1) — 65KB
- img112559081_0.jpg (GRAPHIC) — 121KB
- 0000950170-24-130436.txt ( ) — 298KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 25, 2024, TuHURA Biosciences, Inc. (the “Company”) issued a press release providing a clinical development and business update. The press release disclosed, among other things, the status of the Company’s IFx2.0 clinical development activities, a development update for the Company’s Delta receptor technology, and the entry into a non-binding letter of intent with Kineta, Inc. for a potential merger transaction under which the Company would acquire the rights to Kineta's KVA12123 VISTA inhibiting antibody. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibit 99.1, will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include but are not limited to express or implied statements regarding TuHURA’s expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding regarding clinical trials and research and development programs, in particular with respect to TuHURA’s IFx-Hu2.0 product candidate and its ADC and PDC development program, and any developments or results in connection therewith; the anticipated timing of the results from those studies and trials; a potential acquisition of rights to Kineta Inc.’s KVA12123 product candidate; expectations regarding the use of capital resources, including the net proceeds from TuHURA’s financing; and the time period over which the combined company’s capital resources will be sufficient to fund its anticipated operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances,
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Document 99.1 Press release issued by TuHURA Biosciences, Inc., dated November 25, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: November 25, 2024 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer